{"id":"alk-tree-ait-4-du","_chembl":null,"modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"The product likely works through allergen-specific immunotherapy mechanisms, gradually desensitizing the immune system to specific allergens. This approach typically involves inducing immune tolerance and shifting the balance from allergic Th2 responses toward regulatory T-cell responses.","oneSentence":"Allergen immunotherapy designed to modulate immune response to specific allergens through controlled exposure."},"_scrapedAt":"2026-03-28T03:21:01.078Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123511,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Palforzia","brand":"Palforzia","company":"Aimmune Therapeutics","rationale":"Allergen immunotherapy for food allergies"},{"name":"Grastek","brand":"Grastek","company":"ALK-Abelló A/S","rationale":"Sublingual allergy immunotherapy tablet"},{"name":"Odactra","brand":"Odactra","company":"ALK-Abelló A/S","rationale":"House dust mite allergy immunotherapy"}],"description":"ALK tree AIT 4 DU is an investigational allergy immunotherapy product developed by ALK-Abelló A/S, currently in Phase 2 clinical development. The treatment is designed to address allergic conditions through allergen-specific immunotherapy, though specific molecular targets and indications have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Allergic conditions","patientPopulation":"Adults and adolescents with specific allergies"}]},"trialDetails":[{"nctId":"NCT01675791","phase":"PHASE2","title":"A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2012-08","conditions":"Birch Pollen Allergy","enrollment":637}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALK tree AIT 4 DU","genericName":"ALK tree AIT 4 DU","companyName":"ALK-Abelló A/S","companyId":"alk-abell-a-s","firstApprovalDate":"","aiSummary":"ALK tree AIT is an allergy immunotherapy tablet used to treat Birch Pollen Allergy. It is available in different doses, including 0.5 DU, 1 DU, and 2 DU, as evaluated in a completed clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}